Why is Concord Biotech falling/rising?

Recent Price Movement and Market Context

Concord Biotech’s share price hit a fresh 52-week low of ₹1,352.30 during intraday trading on 08-Dec, marking a 3.69% decline from previous levels. The stock underperformed its sector by 1.81% on the day, with a weighted average price indicating that most trading volume occurred near the day’s low. This suggests selling pressure dominated throughout the session. Furthermore, the stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a bearish trend and weak technical momentum.

Investor participation has also waned, with delivery volumes on 05-Dec falling by 27.32% compared to the five-day average. Although liquidity remains adequate for moderate trade sizes, the reduced investor engagement points to diminished confidence in the stock’s near-term prospects.

Financial Performance Weighing on Sentiment

Concord Biotech’s recent financial disclosures have contributed significantly to the negative sentiment. The company reported a sharp 32.1% decline in profit before tax excluding other income (PBT LESS OI) for the quarter ended September 2025, amounting to ₹72.33 crore. This downturn contrasts unfavourably with the previous four-quarter average, signalling operational challenges.

Operating cash flow for the year stood at a low ₹244.52 crore, reflecting constrained liquidity generation. Additionally, the company’s profit after tax (PAT) over the latest six months declined by 30.7%, reaching ₹107.64 crore. These figures underscore a weakening earnings trajectory that has failed to inspire investor confidence.

Long-term growth metrics also paint a concerning picture. Operating profit has contracted at an annualised rate of 0.48% over the past five years, indicating stagnation rather than expansion. This sluggish growth contrasts sharply with the broader market’s positive returns, as the Sensex has gained 8.91% year-to-date and 4.15% over the last year, while Concord Biotech’s stock has fallen 38.44% and 37.48% respectively over the same periods.

Valuation and Return Considerations

Despite a respectable return on equity (ROE) of 19.17%, the stock’s valuation appears stretched. With a price-to-book value ratio of 7.8, Concord Biotech is priced expensively relative to its peers’ historical averages. This premium valuation is difficult to justify given the company’s declining profits and underwhelming growth prospects.

The stock’s underperformance extends beyond the recent year, having lagged the BSE500 index over the last three years, one year, and three months. This persistent underperformance, combined with deteriorating fundamentals, has likely contributed to the sustained selling pressure and price decline.

Balance of Strengths and Weaknesses

On the positive side, Concord Biotech benefits from a low debt-to-equity ratio, effectively zero, which reduces financial risk. The company also enjoys strong promoter ownership and management efficiency, as reflected in its high ROE. However, these strengths have not been sufficient to offset the negative impact of declining profits and weak operational cash flows.

Given the combination of poor recent earnings, subdued long-term growth, expensive valuation, and technical weakness, the stock’s decline on 08-Dec is consistent with broader investor concerns. The market appears to be pricing in the challenges facing Concord Biotech, resulting in its underperformance relative to benchmarks and sector peers.

Investors should carefully weigh these factors when considering exposure to Concord Biotech, especially in light of its recent financial results and valuation metrics.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →